Article in Aging cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Nisi JiangSam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0000-0003-1837-7618
Jiyuan YinSam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0009-0008-5552-1790
Noah LawrenceSam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Jieyi MengChildren's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.ORCID 0009-0001-3829-9648
Laurence T MaeyensSam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0009-0000-0629-8109
Ziying XuSam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0000-0003-3725-7726
Xin LiSam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Mbolle EkaneSam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Ariana ChaudharySam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Pengju CaoSam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Guannan LiSam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-6070-5008
Carolina Solis-HerreraDivision of Endocrinology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Yi ZhuChildren's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0003-1650-1363
Shangang ZhaoSam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-9209-8206
Funding
TRANSGENIC COREP30AG013319 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI JAMES FLOYD NELSON · 1995 to 2026
$30.6M
Effects of leptin modulation on health span and lifespanR01AG084646 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Shangang Zhao · 2024 to 2026
$2.0M
Enhancing metabolic action of FGF21 through adipocyte Connexin43 gap junction channelsR01DK136619 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Yi Zhu · 2023 to 2026
$1.8M
Postprandial activation of hyaluronan-MARCO axis contributes to systemic chronic inflammationR01DK136532 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Yi Zhu · 2023 to 2026
$1.7M
Paracrine effects of leptin in regulating visceral fat expansionR01DK138035 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Shangang Zhao · 2024 to 2026
$1.2M
Impact of a Novel Secreted Enzyme J18 on Healthspan and LifespanR00AG068239 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ZHAO, SHANGANG · 2023 to 2025
$742k
Impact of a Novel Secreted Enzyme J18 on Healthspan and LifespanK99AG068239 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI ZHAO, SHANGANG · 2021 to 2022
GLP-1-based therapy is highly effective in combating aging-associated metabolic diseases. However, the metabolic effects of frequent withdrawal from this therapy in aged, obese mice have not been previously studied. In this study, aged obese UM-HET3 mice were assigned to three groups: Group 1 received no liraglutide treatment (Lira OFF); Group 2 underwent 3 cycles of treatment followed by withdrawal (Lira ON/OFF); and Group 3 remained on continuous treatment (Lira ON). As expected, mice in Group 3 showed reduced body weight and food intake, along with improved metabolic health. In contrast, mice in Group 2 developed hyperleptinemia and visceral fat expansion, leading to impaired metabolic health. Importantly, although these mice regained their fat mass after each treatment cycle, they failed to restore lean mass, an unfavorable shift in body composition that may increase vulnerability to aging-related sarcopenia. These findings suggest that continuous GLP-1-based therapy is necessary to sustain metabolic benefits, while intermittent use may promote age-associated sarcopenia and metabolic decline.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Repeated Withdrawal of a GLPR Agonist Induces Hyperleptinemia and Deteriorates Metabolic Health in Obese Aging UM-HET3 Mice. · full record | Socratic